Barbara Caleen Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barbara Caleen Hansen has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Heidi K. Ortmeyer
Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
2 shared publications- Kikuko Hotta
Department of Medical Innovation, Osaka University Hospital, Osaka, Japan
2 shared publications Noni L. Bodkin
Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland
2 shared publicationsThomas A. Gustafson
2 shared publications- Agnes Bénardeau
F. Hoffmann-La Roche AG, Basel, Switzerland
1 shared publication Alice S. Ryan
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland
1 shared publication
Latest Publications
- Open Access
Longitudinal dynamics of body weight change in the development of type 2 diabetes
Objective: The aim of this study was to test the obesity–type 2 diabetes mellitus (T2DM) link in the context of longitudinal changes in body weight during the progression to diabetes in mature adult nonhuman primates (NHP).Design and Methods: A colony of 245 adult rhesus monkeys aged 8‐41 years with 179 males were used to define overweight in males as a body weight: ≥13.5 kg or body fat (BF) ≥18% and obesity as ≥16.5 kg or BF ≥27%, and overweight in nonpregnant females was identified as a body weight >8.5 kg or BF >21% and obesity as ≥10.5 kg or BF ≥30%. A subgroup of 48 males (24 T2DM and 24 age‐matched non‐T2DM) males were studied before and following the onset of overt T2DM for the effects of changes in body weight and obesity in inducing this conversion to overt T2DM.Results: Three years before overt T2DM, mean body weight was 18.4 ± 3.3 kg. The DM‐destined group body weight was 3.2 ± 1.1 kg greater and had a longer duration and greater severity of obesity, with peak body weight reached at 3.2 ± 1.8 years before overt T2DM. At DM onset the two groups did not differ significantly in body weight or adiposity.Conclusions: The natural progression from pre‐DM to overt T2DM is caused neither by the amount of excess body weight at DM onset nor by the proximate increases in body weight/adiposity during the pre‐DM period of impaired glucose tolerance. Obesity was, however, essential preceding all NHP cases that developed T2DM.
Open AccessLongitudinal dynamics of body weight change in the development of type 2 diabetes
Objective: The aim of this study was to test the obesity–type 2 diabetes mellitus (T2DM) link in the context of longitudinal changes in body weight during the progression to diabetes in mature adult nonhuman primates (NHP).Design and Methods: A colony of 245 adult rhesus monkeys aged 8‐41 years with 179 males were used to define overweight in males as a body weight: ≥13.5 kg or body fat (BF) ≥18% and obesity as ≥16.5 kg or BF ≥27%, and overweight in nonpregnant females was identified as a body weight >8.5 kg or BF >21% and obesity as ≥10.5 kg or BF ≥30%. A subgroup of 48 males (24 T2DM and 24 age‐matched non‐T2DM) males were studied before and following the onset of overt T2DM for the effects of changes in body weight and obesity in inducing this conversion to overt T2DM.Results: Three years before overt T2DM, mean body weight was 18.4 ± 3.3 kg. The DM‐destined group body weight was 3.2 ± 1.1 kg greater and had a longer duration and greater severity of obesity, with peak body weight reached at 3.2 ± 1.8 years before overt T2DM. At DM onset the two groups did not differ significantly in body weight or adiposity.Conclusions: The natural progression from pre‐DM to overt T2DM is caused neither by the amount of excess body weight at DM onset nor by the proximate increases in body weight/adiposity during the pre‐DM period of impaired glucose tolerance. Obesity was, however, essential preceding all NHP cases that developed T2DM.
- 18 July 2012
- Published by Springer Nature
- Vol. 933, 177-185
Investigation and Treatment of Type 2 Diabetes in Nonhuman Primates
Nonhuman primates provide the ideal animal model for discovering and examining further the mechanisms underlying human type 2 diabetes mellitus. In all aspects studied to date the nonhuman primate has been shown to develop the same disease with the same features that develop in overweight middle-aged humans. This includes the progressive development of the known complications of diabetes, all of which are extraordinarily like those identified in humans. In addition, for the development and evaluation of new therapeutic agents, the translation of findings from nonhuman primates to application in humans has been highly predictable. Both therapeutic efficacy and identification of potential adverse responses can be effectively examined in nonhuman primates due to their great similarity to humans at the molecular, biochemical, and physiological levels. This chapter provides guidance for the development and management of a colony of monkeys with naturally occurring type 2 diabetes mellitus.
- 18 July 2012
- Published by Springer Nature
- Vol. 933, 177-185
Investigation and Treatment of Type 2 Diabetes in Nonhuman Primates
Nonhuman primates provide the ideal animal model for discovering and examining further the mechanisms underlying human type 2 diabetes mellitus. In all aspects studied to date the nonhuman primate has been shown to develop the same disease with the same features that develop in overweight middle-aged humans. This includes the progressive development of the known complications of diabetes, all of which are extraordinarily like those identified in humans. In addition, for the development and evaluation of new therapeutic agents, the translation of findings from nonhuman primates to application in humans has been highly predictable. Both therapeutic efficacy and identification of potential adverse responses can be effectively examined in nonhuman primates due to their great similarity to humans at the molecular, biochemical, and physiological levels. This chapter provides guidance for the development and management of a colony of monkeys with naturally occurring type 2 diabetes mellitus.
- 15 January 2011
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 14 (2) , 207-219
Insulin Signaling and Insulin Sensitizing in Muscle and Liver of Obese Monkeys: Peroxisome Proliferator-Activated Receptor Gamma Agonist Improves Defective Activation of Atypical Protein Kinase C
Obesity, the metabolic syndrome, and aging share several pathogenic features in both humans and non-human primates, including insulin resistance and inflammation. Since muscle and liver are considered key integrators of metabolism, we sought to determine in biopsies from lean and obese aging rhesus monkeys the nature of defects in insulin activation and, further, the potential for mitigation of such defects by an in vivo insulin sensitizer, rosiglitazone, and a thiazolidinedione activator of the peroxisome proliferator-activated receptor gamma. The peroxisome proliferator-activated receptor gamma agonist reduced hyperinsulinemia, improved insulin sensitivity, lowered plasma triglycerides and free fatty acids, and increased plasma adiponectin. In muscle of obese monkeys, previously shown to exhibit defective insulin signaling, the insulin sensitizer improved insulin activation of atypical protein kinase C (aPKC), the defective direct activation of aPKC by phosphatidylinositol (PI)-3,4,5-(PO4)3, and 5′-AMP-activated protein kinase and increased carnitine palmitoyltransferase-1 mRNA expression, but it did not improve insulin activation of insulin receptor substrate (IRS)-1-dependent PI 3-kinase (IRS-1/PI3K), protein kinase B, or glycogen synthase. We found that, although insulin signaling was impaired in muscle, insulin activation of IRS-1/PI3K, IRS-2/PI3K, protein kinase B, and aPKC was largely intact in liver and that rosiglitazone improved insulin signaling to aPKC in muscle by improving responsiveness to PI-3,4,5-(PO4)3. Antioxid. Redox Signal. 14, 207–219.
- 15 January 2011
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 14 (2) , 207-219
Insulin Signaling and Insulin Sensitizing in Muscle and Liver of Obese Monkeys: Peroxisome Proliferator-Activated Receptor Gamma Agonist Improves Defective Activation of Atypical Protein Kinase C
Obesity, the metabolic syndrome, and aging share several pathogenic features in both humans and non-human primates, including insulin resistance and inflammation. Since muscle and liver are considered key integrators of metabolism, we sought to determine in biopsies from lean and obese aging rhesus monkeys the nature of defects in insulin activation and, further, the potential for mitigation of such defects by an in vivo insulin sensitizer, rosiglitazone, and a thiazolidinedione activator of the peroxisome proliferator-activated receptor gamma. The peroxisome proliferator-activated receptor gamma agonist reduced hyperinsulinemia, improved insulin sensitivity, lowered plasma triglycerides and free fatty acids, and increased plasma adiponectin. In muscle of obese monkeys, previously shown to exhibit defective insulin signaling, the insulin sensitizer improved insulin activation of atypical protein kinase C (aPKC), the defective direct activation of aPKC by phosphatidylinositol (PI)-3,4,5-(PO4)3, and 5′-AMP-activated protein kinase and increased carnitine palmitoyltransferase-1 mRNA expression, but it did not improve insulin activation of insulin receptor substrate (IRS)-1-dependent PI 3-kinase (IRS-1/PI3K), protein kinase B, or glycogen synthase. We found that, although insulin signaling was impaired in muscle, insulin activation of IRS-1/PI3K, IRS-2/PI3K, protein kinase B, and aPKC was largely intact in liver and that rosiglitazone improved insulin signaling to aPKC in muscle by improving responsiveness to PI-3,4,5-(PO4)3. Antioxid. Redox Signal. 14, 207–219.
- Open Access
- 1 January 2011
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 10 (1) , 7
Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major therapeutic goals in individuals with type 2 diabetes mellitus (T2DM). This study was performed to evaluate the effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ (PPARα/γ) agonist, on both lipid and glycemic parameters in obese, hypertriglyceridemic, insulin-resistant rhesus monkeys.
- 1 January 2011
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 10 (1) , 7
Open AccessEffects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
Glycemic control and management of dyslipidemia to reduce cardiovascular risk are major therapeutic goals in individuals with type 2 diabetes mellitus (T2DM). This study was performed to evaluate the effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ (PPARα/γ) agonist, on both lipid and glycemic parameters in obese, hypertriglyceridemic, insulin-resistant rhesus monkeys.
- Open Access
- 16 August 2007
- Published by Springer Nature in BMC Medical Genetics
- Vol. 8 (1) , 55
PPARα L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males
Background: Of the five sub-phenotypes defining metabolic syndrome, all are known to have strong genetic components (typically 50–80% of population variation). Studies defining genetic predispositions have typically focused on older populations with metabolic syndrome and/or type 2 diabetes. We hypothesized that the study of younger populations would mitigate many confounding variables, and allow us to better define genetic predisposition loci for metabolic syndrome. Methods: We studied 610 young adult volunteers (average age 24 yrs) for metabolic syndrome markers, and volumetric MRI of upper arm muscle, bone, and fat pre- and post-unilateral resistance training. Results: We found the PPARα L162V polymorphism to be a strong determinant of serum triglyceride levels in young White males, where carriers of the V allele showed 78% increase in triglycerides relative to L homozygotes (LL = 116 ± 11 mg/dL, LV = 208 ± 30 mg/dL; p = 0.004). Men with the V allele showed lower HDL (LL = 42 ± 1 mg/dL, LV = 34 ± 2 mg/dL; p = 0.001), but women did not. Subcutaneous fat volume was higher in males carrying the V allele, however, exercise training increased fat volume of the untrained arm in V carriers, while LL genotypes significantly decreased in fat volume (LL = -1,707 ± 21 mm3, LV = 17,617 ± 58 mm3 ; p = 0.002), indicating a systemic effect of the V allele on adiposity after unilateral training. Our study suggests that the primary effect of PPARα L162V is on serum triglycerides, with downstream effects on adiposity and response to training. Conclusion: Our results on association of PPARα and triglycerides in males showed a much larger effect of the V allele than previously reported in older and less healthy populations. Specifically, we showed the V allele to increase triglycerides by 78% (p = 0.004), and this single polymorphism accounted for 3.8% of all variation in serum triglycerides in males (p = 0.0037).
- 16 August 2007
- Published by Springer Nature in BMC Medical Genetics
- Vol. 8 (1) , 55
Open AccessPPARα L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males
Background: Of the five sub-phenotypes defining metabolic syndrome, all are known to have strong genetic components (typically 50–80% of population variation). Studies defining genetic predispositions have typically focused on older populations with metabolic syndrome and/or type 2 diabetes. We hypothesized that the study of younger populations would mitigate many confounding variables, and allow us to better define genetic predisposition loci for metabolic syndrome. Methods: We studied 610 young adult volunteers (average age 24 yrs) for metabolic syndrome markers, and volumetric MRI of upper arm muscle, bone, and fat pre- and post-unilateral resistance training. Results: We found the PPARα L162V polymorphism to be a strong determinant of serum triglyceride levels in young White males, where carriers of the V allele showed 78% increase in triglycerides relative to L homozygotes (LL = 116 ± 11 mg/dL, LV = 208 ± 30 mg/dL; p = 0.004). Men with the V allele showed lower HDL (LL = 42 ± 1 mg/dL, LV = 34 ± 2 mg/dL; p = 0.001), but women did not. Subcutaneous fat volume was higher in males carrying the V allele, however, exercise training increased fat volume of the untrained arm in V carriers, while LL genotypes significantly decreased in fat volume (LL = -1,707 ± 21 mm3, LV = 17,617 ± 58 mm3 ; p = 0.002), indicating a systemic effect of the V allele on adiposity after unilateral training. Our study suggests that the primary effect of PPARα L162V is on serum triglycerides, with downstream effects on adiposity and response to training. Conclusion: Our results on association of PPARα and triglycerides in males showed a much larger effect of the V allele than previously reported in older and less healthy populations. Specifically, we showed the V allele to increase triglycerides by 78% (p = 0.004), and this single polymorphism accounted for 3.8% of all variation in serum triglycerides in males (p = 0.0037).
- 1 June 2001
- Published by Taylor & Francis
- Vol. 109, 3-9
Emerging strategies for weight management.
Obesity is a chronic disease that is increasing in prevalence. It is associated with other chronic conditions because excess weight in obese individuals substantially increases the risk of type II diabetes mellitus, coronary heart disease (CHD), hypertension, and gallbladder disease. Yet modest weight loss (5% to 10% of body weight) improves risk factors for cardiovascular disease and diabetes. Current recommendations for reduction of CHD risk and treatment of diabetes and hypertension include weight reduction, when indicated. Pharmacotherapy can significantly increase weight loss and improve weight-loss maintenance when included in a program of decreased food intake and increased activity. Numerous calls to action have been made to develop coordinated clinical and public health strategies for preventing and treating obesity. This series of articles, based on a symposium presented at the North American Association for the Study of Obesity 2000 annual meeting, summarizes current concepts concerning the origins of obesity, its comorbid conditions, and its effective treatment. Also included is a review of the costs of obesity to the healthcare system in terms of productivity losses and other expenses.
- 1 June 2001
- Published by Taylor & Francis
- Vol. 109, 3-9
Emerging strategies for weight management.
Obesity is a chronic disease that is increasing in prevalence. It is associated with other chronic conditions because excess weight in obese individuals substantially increases the risk of type II diabetes mellitus, coronary heart disease (CHD), hypertension, and gallbladder disease. Yet modest weight loss (5% to 10% of body weight) improves risk factors for cardiovascular disease and diabetes. Current recommendations for reduction of CHD risk and treatment of diabetes and hypertension include weight reduction, when indicated. Pharmacotherapy can significantly increase weight loss and improve weight-loss maintenance when included in a program of decreased food intake and increased activity. Numerous calls to action have been made to develop coordinated clinical and public health strategies for preventing and treating obesity. This series of articles, based on a symposium presented at the North American Association for the Study of Obesity 2000 annual meeting, summarizes current concepts concerning the origins of obesity, its comorbid conditions, and its effective treatment. Also included is a review of the costs of obesity to the healthcare system in terms of productivity losses and other expenses.
- 1 June 2001
- Published by Taylor & Francis
- Vol. 109, 40-4
Emerging strategies for weight management. Summary.
Obesity is a significant health problem in the United States today and is associated with increased risk of cardiovascular disease, diabetes, and other chronic conditions. Weight loss improves obesity-related health complications and may decrease their incidence as well.
- 1 June 2001
- Published by Taylor & Francis
- Vol. 109, 40-4
Emerging strategies for weight management. Summary.
Obesity is a significant health problem in the United States today and is associated with increased risk of cardiovascular disease, diabetes, and other chronic conditions. Weight loss improves obesity-related health complications and may decrease their incidence as well.
- 1 March 2001
- Published by Elsevier in The Journal of Nutrition
- Vol. 131 (3) , 900S-902S
Introduction
At this time of increasing attention to the worldwide problem of obesity and its negative consequences for health and well being, it is timely to present a symposium on the effects of calorie restriction and the potential for calorie restriction mimetic therapies. The present symposium “Calorie Restriction: Effects on Body Composition, Insulin Signaling and Aging” was included in the Experimental Biology 2000 meeting held April 15–18, 2000 in San Diego, California. It is now recognized that calorie restriction carries with it many heretofore unrecognized consequences in addition to the life span–extending properties first described in the 1930s. This symposium addresses some of the current issues in calorie restriction and demonstrates the widespread effects that may underlie recidivism after weight loss, as well as the metabolically positive consequences for health of long-term calorie restraint.
- 1 March 2001
- Published by Elsevier in The Journal of Nutrition
- Vol. 131 (3) , 900S-902S
Introduction
At this time of increasing attention to the worldwide problem of obesity and its negative consequences for health and well being, it is timely to present a symposium on the effects of calorie restriction and the potential for calorie restriction mimetic therapies. The present symposium “Calorie Restriction: Effects on Body Composition, Insulin Signaling and Aging” was included in the Experimental Biology 2000 meeting held April 15–18, 2000 in San Diego, California. It is now recognized that calorie restriction carries with it many heretofore unrecognized consequences in addition to the life span–extending properties first described in the 1930s. This symposium addresses some of the current issues in calorie restriction and demonstrates the widespread effects that may underlie recidivism after weight loss, as well as the metabolically positive consequences for health of long-term calorie restraint.
- 1 December 1999
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 52 (2) , 56-60
Calorie restriction in nonhuman primates: mechanisms of reduced morbidity and mortality
Long term chronic calorie restriction (CR) of adult nonhuman primates significantly reduces morbidity and increases median age of death. The present review is focused upon an ongoing study of sustained adult-onset calorie restriction, which has been underway for 15 years. Monkeys, initially calorie restricted at about 10 years of age, are now approximately 25 years old. The median life span of these restricted monkeys is increasing, now exceeding that of ad libitum (AL)-fed monkeys. In our laboratory, maximum life span for AL-fed monkeys appears to be about 40 years. Thus, whether CR can also increase maximal life span, as it does in rodents, cannot be determined for at least another 15 years. The earliest detectable positive benefit on morbidity in these monkeys was previously reported as the prevention of obesity. Current evidence, as reviewed here, suggests that much obesity-associated morbidity is also mitigated by sustained calorie restraint in nonhuman primates. Furthermore, probably because of the prevention of obesity, diabetes has also been prevented. Recent findings include the identification of extraordinary changes in the glycogen synthesis pathway, and on the phosphorylation of glycogen synthase in response to insulin. This calorie restriction-induced prevention of morbidity does not require excessive leanness, but is clearly present when body fat is within the normal range of 10 to 22%, and this is likely to be true in humans as well.
- 1 December 1999
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 52 (2) , 56-60
Calorie restriction in nonhuman primates: mechanisms of reduced morbidity and mortality
Long term chronic calorie restriction (CR) of adult nonhuman primates significantly reduces morbidity and increases median age of death. The present review is focused upon an ongoing study of sustained adult-onset calorie restriction, which has been underway for 15 years. Monkeys, initially calorie restricted at about 10 years of age, are now approximately 25 years old. The median life span of these restricted monkeys is increasing, now exceeding that of ad libitum (AL)-fed monkeys. In our laboratory, maximum life span for AL-fed monkeys appears to be about 40 years. Thus, whether CR can also increase maximal life span, as it does in rodents, cannot be determined for at least another 15 years. The earliest detectable positive benefit on morbidity in these monkeys was previously reported as the prevention of obesity. Current evidence, as reviewed here, suggests that much obesity-associated morbidity is also mitigated by sustained calorie restraint in nonhuman primates. Furthermore, probably because of the prevention of obesity, diabetes has also been prevented. Recent findings include the identification of extraordinary changes in the glycogen synthesis pathway, and on the phosphorylation of glycogen synthase in response to insulin. This calorie restriction-induced prevention of morbidity does not require excessive leanness, but is clearly present when body fat is within the normal range of 10 to 22%, and this is likely to be true in humans as well.
- Open Access
- 1 December 1999
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 52 (90001) , 56-60
Calorie restriction in nonhuman primates: mechanisms of reduced morbidity and mortality
Long term chronic calorie restriction (CR) of adult nonhuman primates significantly reduces morbidity and increases median age of death. The present review is focused upon an ongoing study of sustained adult-onset calorie restriction, which has been underway for 15 years. Monkeys, initially calorie restricted at about 10 years of age, are now approximately 25 years old. The median life span of these restricted monkeys is increasing, now exceeding that of ad libitum (AL)-fed monkeys. In our laboratory, maximum life span for AL-fed monkeys appears to be about 40 years. Thus, whether CR can also increase maximal life span, as it does in rodents, cannot be determined for at least another 15 years. The earliest detectable positive benefit on morbidity in these monkeys was previously reported as the prevention of obesity. Current evidence, as reviewed here, suggests that much obesity-associated morbidity is also mitigated by sustained calorie restraint in nonhuman primates. Furthermore, probably because of the prevention of obesity, diabetes has also been prevented. Recent findings include the identification of extraordinary changes in the glycogen synthesis pathway, and on the phosphorylation of glycogen synthase in response to insulin. This calorie restriction-induced prevention of morbidity does not require excessive leanness, but is clearly present when body fat is within the normal range of 10 to 22%, and this is likely to be true in humans as well.
- 1 December 1999
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 52 (90001) , 56-60
Open AccessCalorie restriction in nonhuman primates: mechanisms of reduced morbidity and mortality
Long term chronic calorie restriction (CR) of adult nonhuman primates significantly reduces morbidity and increases median age of death. The present review is focused upon an ongoing study of sustained adult-onset calorie restriction, which has been underway for 15 years. Monkeys, initially calorie restricted at about 10 years of age, are now approximately 25 years old. The median life span of these restricted monkeys is increasing, now exceeding that of ad libitum (AL)-fed monkeys. In our laboratory, maximum life span for AL-fed monkeys appears to be about 40 years. Thus, whether CR can also increase maximal life span, as it does in rodents, cannot be determined for at least another 15 years. The earliest detectable positive benefit on morbidity in these monkeys was previously reported as the prevention of obesity. Current evidence, as reviewed here, suggests that much obesity-associated morbidity is also mitigated by sustained calorie restraint in nonhuman primates. Furthermore, probably because of the prevention of obesity, diabetes has also been prevented. Recent findings include the identification of extraordinary changes in the glycogen synthesis pathway, and on the phosphorylation of glycogen synthase in response to insulin. This calorie restriction-induced prevention of morbidity does not require excessive leanness, but is clearly present when body fat is within the normal range of 10 to 22%, and this is likely to be true in humans as well.